MarketCap
Facebook
X
Telegram
Apellis Pharmaceuticals Revenue | APLS
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Apellis Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 B | 781 M | 397 M | 75.4 M | 66.6 M | 251 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1 B | 66.6 M | 429 M |
Quarterly Revenue Apellis Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 268 M | 459 M | 178 M | 167 M | - | 197 M | 200 M | 172 M | - | 110 M | 95 M | 44.8 M | - | 22.1 M | 16.3 M | 14.4 M | - | 5.65 M | 623 K | - | - | 646 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 459 M | 623 K | 122 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Celsion Corporation
CLSN
|
500 K | - | -6.63 % | $ 13.9 M |  USA |
 |
FSD Pharma
HUGE
|
257 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Qilian International Holding Group Limited
QLI
|
37.9 M | - | -6.08 % | $ 184 M |  China |
 |
Happiness Biotech Group Limited
HAPP
|
71.5 K | - | 1.35 % | $ 17.8 M | China |
 |
Dynavax Technologies Corporation
DVAX
|
277 M | - | - | $ 2.02 B | USA |
 |
BioXcel Therapeutics
BTAI
|
642 K | $ 1.19 | 5.31 % | $ 14.5 M | USA |
 |
Burford Capital Limited
BUR
|
413 M | $ 4.37 | 0.23 % | $ 958 M |  Britain |
 |
I-Mab
IMAB
|
27.6 M | - | - | $ 866 M | China |
 |
BeyondSpring
BYSI
|
1.35 M | $ 0.84 | 34.27 % | $ 34.5 M | USA |
 |
AgeX Therapeutics
AGE
|
130 K | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
70.9 M | - | 2.54 % | $ 160 B |  France |
 |
Cerus Corporation
CERS
|
234 M | $ 2.98 | 4.93 % | $ 568 M | USA |
 |
Compugen Ltd.
CGEN
|
72.8 M | $ 2.41 | 4.17 % | $ 225 M |  Israel |
 |
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M |  Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
Abcam plc
ABCM
|
362 M | - | - | $ 4.9 B | Britain |
 |
Завод ДИОД
DIOD
|
517 M | - | - | - |  Russia |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M | Britain |
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M | Germany |
|
Champions Oncology
CSBR
|
59.4 M | $ 5.1 | 2.63 % | $ 70.5 M | USA |
 |
Affimed N.V.
AFMD
|
8.28 M | - | -34.95 % | $ 21.5 M | Germany |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
12 M | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
5 K | - | - | $ 12.5 M |  Belgium |
 |
Generation Bio Co.
GBIO
|
19.9 M | - | - | $ 344 M | USA |
 |
AnaptysBio
ANAB
|
235 M | $ 58.47 | 4.37 % | $ 1.68 B | USA |
 |
Anika Therapeutics
ANIK
|
113 M | $ 21.5 | 1.56 % | $ 308 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
43 K | - | -4.36 % | $ 27 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
77.1 M | $ 15.47 | 1.91 % | $ 2.08 B | Canada |
 |
GlycoMimetics
GLYC
|
10.8 M | - | 9357.83 % | $ 1.01 B | USA |
 |
Aeterna Zentaris
AEZS
|
7.5 M | - | 5.93 % | $ 314 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
5.34 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bicycle Therapeutics plc
BCYC
|
72.6 M | $ 3.9 | 0.24 % | $ 270 M | Britain |
 |
Beam Therapeutics
BEAM
|
140 M | $ 26.75 | 0.91 % | $ 2.65 B | USA |
 |
AIkido Pharma
AIKI
|
123 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
3.22 B | $ 67.36 | 0.99 % | $ 12.9 B | USA |